top of page

Our Tests

mediscan targets some of the costliest diseases' early detection and chronic disease management for liver, lungs, kidney and more.

Our aim is to shift the emphasis of the healthcare system from its current treatment oriented, hospital based structure to a prevention focused, community based system

 

The Liver

Liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 2 billion people globally

Two billion people have NAFLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) around the World

mediscan screens for MASLD by estimating clinical ultrasound and MRI liver-derived fat percentage scores. 

Live - NAFLD

In Hong Kong

  • 42% of the population has MASLD

  • 1 in 5 have lean-MASLD

  • 73% of diabetics have MASLD

The Lungs

Lung disease

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide 

COPD third leading cause of death worldwide

mediscan screens for lung chronic diseases such as COPD, asthma, fibrosis, interstitial lung disease and long COVID by estimating clinical spirometry lung volume parameters. 

Lung - COPD

In Hong Kong

  • 5th biggest killer is COPD

  • 1223 registered deaths, 2.7% of all deaths in Hong Kong from COPD

  • 30,000 episodes of inpatient discharges and deaths

The Kidney

Kidney disease

Chronic kidney disease (CKD) affects around 10% of the world's population.

 

9 out of 10 people are unaware they have the disease.

One in ten have CKD

mediscan screens for CKD by estimating the clinical standard on the kidney's ability to filter waste products from the blood. 

In Hong Kong

  • 1 in 7 have hidden kidney diseases

  • 1 in 3 with diabetes and 1 in 5 with hypertension have CKD

  • 50% mortality rate for hemodialysis patients over 65 years old

bottom of page